Overview
ARWR market data
Price History
ARWR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.01 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -47.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.10 – $95.49 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $12.2B · P/B 10.04 · P/S 18.24.
Company News
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120Benzinga · Aug 6, 2026, 6:44 PM
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M EstimateBenzinga · Aug 4, 2026, 8:02 PM
Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026Benzinga · Aug 4, 2026, 8:02 PM
B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123Benzinga · Jul 30, 2026, 4:30 PM
Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jul 27, 2026, 11:58 AM
Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial HypercholesterolemiaBenzinga · Jul 27, 2026, 11:36 AM
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115Benzinga · Jul 27, 2026, 10:08 AM
Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120Benzinga · Jul 23, 2026, 6:00 PM
Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126Benzinga · Jul 23, 2026, 2:12 PM
Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115Benzinga · Jul 22, 2026, 7:23 PM